News headlines about resTORbio (NASDAQ:TORC) have trended somewhat negative on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. resTORbio earned a media sentiment score of -0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 48.8257219417407 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of brokerages have recently issued reports on TORC. Bank of America began coverage on resTORbio in a report on Tuesday, February 20th. They issued a “buy” rating and a $23.00 target price for the company. Leerink Swann began coverage on resTORbio in a report on Tuesday, February 20th. They issued an “outperform” rating and a $36.00 target price for the company. Evercore ISI began coverage on resTORbio in a report on Tuesday, February 20th. They issued an “outperform” rating and a $28.00 target price for the company. Finally, Wedbush began coverage on resTORbio in a research report on Tuesday, February 20th. They set an “outperform” rating and a $30.00 price target on the stock.
NASDAQ TORC opened at $8.53 on Wednesday. The company has a market cap of $250.17 and a P/E ratio of -1.01. resTORbio has a one year low of $7.55 and a one year high of $21.10.
resTORbio (NASDAQ:TORC) last announced its quarterly earnings data on Thursday, March 29th. The company reported ($5.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($4.08). analysts anticipate that resTORbio will post -1.46 earnings per share for the current year.
In related news, major shareholder Puretech Health Llc purchased 233,333 shares of resTORbio stock in a transaction dated Tuesday, January 30th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $3,499,995.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc purchased 533,333 shares of resTORbio stock in a transaction dated Tuesday, January 30th. The stock was bought at an average price of $15.00 per share, for a total transaction of $7,999,995.00. The disclosure for this purchase can be found here. Insiders acquired a total of 770,666 shares of company stock worth $11,534,810 over the last quarter.
COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/25/restorbio-torc-earning-somewhat-negative-press-coverage-study-shows.html.
resTORbio Company Profile
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.